Dr. Wassim McHayleh Breast Cancer Research Patient Story - Florida Trend

Janisette Rivera-Rollins, a sixth-grade teacher and mother of two from Central Florida, never imagined that a clinical trial would change the course of her life. Diagnosed with triple-negative breast cancer (TNBC) in 2022 — a particularly aggressive and hard-to-treat form of the disease — she endured months of traditional chemotherapy, immunotherapy, surgery, and radiation. While those treatments shrank her tumor, they didn’t eliminate it. Then came a new opportunity: a clinical trial testing an investigational drug called datopotamab deruxtecan at AdventHealth Cancer Institute. After much prayer and with the support of her care team, Janisette enrolled — becoming the first Central Florida participant in this global study. Just five months later, on her 34th birthday, she was declared cancer-free.

Now being closely monitored by Dr. Wassim McHayleh and his team, Janisette’s story represents a promising future in cancer care. The drug she received belongs to a new class of therapies known as antibody-drug conjugates, which target cancer cells directly to maximize effectiveness while minimizing side effects. As the trial continues to enroll patients across the region, researchers hope this treatment may set a new standard for TNBC, a disease that disproportionately affects younger women and women of color. For Janisette — and the many patients who will follow — it’s more than a clinical advancement; it’s a second chance at life. Read the full story by clicking the button below.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
AdventHealth’s Karen D. Corbin, PhD, RD, Contributed to New American Diabetes Association Consensus Statement on Liver Disease in Diabetes

Metabolic dysfunction associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at...

Read Article about "AdventHealth’s Karen D. Corbin, PhD, RD, Contributed to New American Diabetes Association Consensus Statement on Liver Disease in Diabetes "
News
AdventHealth Research Institute and NESTRE Health & Performance Announce Collaboration to Advance Neurocognitive Health and Performance Through Cognitive Training

“We are at a pivotal point in our understanding of neuroscience and in particular, neuroplasticity – the ability of neural networks in the brain to change through growth and reorganization. This new...

Read Article about "AdventHealth Research Institute and NESTRE Health and Performance Announce Collaboration to Advance Neurocognitive Health and Performance Through Cognitive Training "
View More Articles